AKEBIA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M | $294.6M | $335.0M |
| Cost of Revenue | — | $39.5M | $63.2M | $74.1M | $85.6M | $150.7M | $296.5M | $145.3M |
| Gross Profit | — | $196.7M | $97.0M | $120.5M | $206.9M | $61.0M | $-1.8M | $189.7M |
| Gross Margin | — | 83.3% | 60.6% | 61.9% | 70.7% | 28.8% | -0.6% | 56.6% |
| Operating Expenses | ||||||||
| Research & Development | — | $62.4M | $37.7M | $63.1M | $130.0M | $147.9M | $218.5M | $323.0M |
| SG&A Expense | — | $107.5M | $106.5M | $100.2M | $138.6M | $174.1M | $154.1M | $149.5M |
| Operating Income | — | $23.5M | $-50.5M | $-46.3M | $-80.8M | $-264.5M | $-377.8M | $-286.3M |
| Operating Margin | — | 9.9% | -31.5% | -23.8% | -27.6% | -125.0% | -128.2% | -85.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-3.7M | $-69.4M | $-51.9M | $-94.2M | $-282.0M | $-384.8M | $-286.3M |
| Income Tax Expense | — | $1.6M | $0 | $0 | $0 | $0 | $0 | $-6.6M |
| Net Income | — | $-5.3M | $-69.4M | $-51.9M | $-94.2M | $-282.0M | $-384.8M | $-279.7M |
| Net Margin | — | -2.3% | -43.3% | -26.7% | -32.2% | -133.3% | -130.6% | -83.5% |
| EPS (Basic) | — | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 |
| EPS (Diluted) | — | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 |
| Shares Outstanding (Basic) | 267.9M | 257.2M | 210.9M | 187.5M | 182.8M | 165.9M | 138.5M | 118.4M |
| Shares Outstanding (Diluted) | 267.9M | 257.2M | 210.9M | 187.5M | 182.8M | 165.9M | 138.5M | 118.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |